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The use of alcohol and other harmful 
substances, such as cocaine, opioids, and 
marijuana during pregnancy has increased 
over the last decades (Sebastiani et al., 2018). 
Using these substances can be very harmful to 
the unborn baby and mother (Viteri et al., 
2015). This fact sheet will cover (1) the 
consequences of substance use and (2) the 
current recommendations for substance use 
during pregnancy.  
 
General Consequences of Substance Use 
One reason using alcohol, tobacco, illicit drugs, 
or misusing prescription medication can be so 
harmful during pregnancy is because many of 
these substances can easily pass through the 
placenta and to the fetus (Jones & Fielder, 
2015; NIDA, 2020a).  
 
Regular maternal use of some drugs during 
pregnancy may cause neonatal abstinence 
syndrome (NAS). NAS is where the infant goes 
through withdrawal at birth (National Institute 
on Drug Abuse [NIDA], 2020a). Research has 
shown opioids (such as heroin or prescription 
pain relievers), alcohol, barbiturates, caffeine, 
and benzodiazepines cause an infant to 
experience withdrawal symptoms at birth. The 
type and severity of the withdrawal symptoms 
in an infant depend on the substance(s), 
length, and frequency of use, and whether the 
infant was born prematurely or full-term (NIDA, 
2020a). 
 
Research has also found an association 
between substance use during pregnancy and 
an increased risk of miscarriage, stillbirth, 
congenital disabilities, premature birth, low 
birth weight, sudden infant death syndrome 
(SIDS), and adverse long-term effects in the 
child (Lind et al., 2017; Viteri et al., 2015).  
 
Seeking treatment and professional help as 
soon as possible for substance use may help 
reduce the health risks for both mother and 
fetus. Figure 1 may help you to evaluate if a 
possible substance abuse disorder exists. 
 
Nutritional Impact of Substance Use 
Nutrition and the mother’s diet are very 
important during pregnancy, helping the fetus 
grow and develop properly. However, 
substance dependency can affect how certain 
nutrients are absorbed in the body and result in 
poor growth and development. For example, 




the absorption of some essential amino acids, 
vitamin A, vitamin C, various B vitamins, and 
folate. All these nutrients are essential to the 
growing fetus (Sebastiani et al., 2018). For 
example, folate deficiency increases the risk of 
neural tube defects in infants (Sebastiani et al., 
2018). Many harmful substances also 
decrease appetite in the user, which during 
pregnancy may not allow for needed energy 
and nutrients to get to the fetus (Sebastiani et 
al., 2018). 
 
Talk with your doctor or medical provider to 
discuss the impact of substance use on 
nutrition during pregnancy. Improving maternal 
diet during pregnancy may help to improve the 
infant’s long-term health outcomes. 
 
Figure 1. Self-Evaluation of Possible 
Substance Abuse Disorder  
Have you ever felt that you ought to cut 
down on your drinking or drug use? 
Have people annoyed you by criticizing your 
drinking or drug use? 
Have you ever felt bad or guilty about your 
drinking or drug use? 
Have you ever had a drink or used drugs first 
thing in the morning to steady your nerves or 
to get rid of a hangover (eye-opener)? 
Scoring: One or more “yes” responses indicate a 
possible substance use disorder and the need for 
further testing. 
Note. Information was adapted from Brown & Rounds, 
1995 and Hinkin et al., 2001. 
 
Sudden Withdrawal Consequences 
Pregnancy brings about many physical 
changes in the mother, alters her body’s 
metabolism, and may alter withdrawal rates. 
The intensity and length of withdrawal may 
depend on how long the substance use has 
occurred, the amount of substance consumed, 
the type, and the intake method (Figure 2). 
Genetics may also influence the withdrawal 
rate (Editorial Staff, 2021).  
 
Physical dependence often accompanies 
substance use. This means if the substance 
use stops suddenly, serious, and possibly life-
threatening, withdrawal symptoms may occur, 
possibly putting the fetus may be put at risk 
(Steele et al., 2020). If opioid-dependent, the 
American College of Obstetricians and 
Gynecologists warns that preterm labor, fetal 
distress, and even fetal death may occur if 
mothers stop substances suddenly. Due to 
these possible consequences, it is not 
recommended, even when pregnant, that 
individuals struggling with substance 
dependence stop "cold turkey" without 
professional guidance and help (Steele et al., 
2020; Editorial Staff, 2021).  
 
Figure 2. General Timeline for Maternal 
Withdrawal Symptoms  
Note. Estimations were provided by the New York State 
Office of Alcoholism and Substance Abuse Services.  
 
Medical Detox 
There are evidence-based treatments for 
pregnant women with substance use disorders 
that may have great benefits. Proper prenatal 
care and participating in a comprehensive drug 
treatment program have been associated with 
improving many of the consequences of 
substance use during pregnancy (NIDA, 
2020b). 
 
A process called medical detoxification is 
generally recommended as the safest for 
women as they strive to stop taking harmful 
substances during pregnancy. Medical 
detoxification is medically supervised and done 
in a safe environment. If necessary, 
medications may be given to help with the 
detoxification process and relieve symptoms. 
While there are no FDA-approved medications 
to help treat substance dependence, NIDA 
reports that there are some low-risk 
replacement medications that may be 
beneficial during detox (2020b). 
 
 
• Alcohol: 6–60 hours 
• Opioids: 12–72 hours 
• Benzodiazepines: 1–12 days 
• Barbiturates: 4–10 days 
 
Medication for Opioid Use Disorder  
For pregnant women with an opioid use 
disorder (OUD), the generally recommended 
therapy is opioid agonist pharmacotherapy 
(Committee on Obstetric Practice, 2017). This 
therapy involves taking medications that may 
help relieve symptoms of substance 
dependence (Global Health Observatory, n.d.). 
Opioid agonist pharmacotherapy is often 
preferable to medically supervised withdrawal 
as withdrawal may be associated with high 
relapse rates, leading to worse outcomes. 
More research is needed to assess the safety 
and long-term outcomes of medically 
supervised withdrawal (Committee on Obstetric 
Practice, 2017).  
 
Two common medications used to treat opioid 
dependence are methadone and 
buprenorphine. Both medications are long-
acting opioid drugs used to replace opioids like 
heroin or prescription painkillers. While these 
medications still carry the risk of an infant 
developing withdrawal symptoms, the infants 
typically have fewer and less severe symptoms 
of withdrawal (Editorial Staff, 2021). These 
medications can only be prescribed by trained 
doctors who hold the proper certification. 
 
Medication for Alcohol Dependency 
During Pregnancy  
We currently have limited data on treating 
pregnant women who misuse alcohol and are 
alcohol-dependent. Benzodiazepines are most 
often prescribed to manage alcohol withdrawal 
symptoms. The research also suggests 
psychosocial interventions, along with 
benzodiazepines, have great success in 
reducing consumption and maintaining sobriety 
(Heberlein et al., 2012). While there is minimal 
preliminary data, support of naltrexone may 
also help treat alcohol dependency among 
pregnant women (Heberlein et al., 2012). It is 
vital to work closely with medical professionals 
to understand the risks associated with the 
withdrawal symptoms and the risks associated 
with the medications that may help those 
withdrawal symptoms.  
 
Conclusion 
Substance or alcohol use during pregnancy 
may be very harmful to both mother and infant. 
Consult with a healthcare provider before 
starting or stopping medications, especially 
during pregnancy. A healthcare provider can 
explain the risks and benefits of detox or 
medication therapy and provide support and 
guidance through that process.  
 
Additional Resources 
Use these websites and resources to find more 
information on treatment for substance use 
during pregnancy. Remember to consult a 
doctor or health professional before starting 
any treatment program. 






• Principles of Drug Addiction Treatment: A 









Women receiving medication 
to treat opioid use are more 
likely to have a baby with a 
healthy birthweight. 
 (Berg et al., 2008) 
 
• Substance Abuse and Mental Health Services 




• Academy of Perinatal Harm Reduction. 
https://www.perinatalharmreduction.org/ 
 
• 1-800-662-HELP (4357). The Substance 
Abuse and Mental Health Services 
Administration National Helpline provides 
treatment referral and information 24/7. It is 
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